Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $7.7 million.

  • Cartesian Therapeutics' Accumulated Expenses fell 1851.46% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 1851.46%. This contributed to the annual value of $12.1 million for FY2024, which is 2245.06% down from last year.
  • Cartesian Therapeutics' Accumulated Expenses amounted to $7.7 million in Q3 2025, which was down 1851.46% from $8.0 million recorded in Q2 2025.
  • Cartesian Therapeutics' Accumulated Expenses' 5-year high stood at $15.6 million during Q4 2023, with a 5-year trough of $6.8 million in Q1 2021.
  • Its 5-year average for Accumulated Expenses is $10.7 million, with a median of $10.5 million in 2021.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 3955.54% in 2022, then tumbled by 3068.86% in 2024.
  • Cartesian Therapeutics' Accumulated Expenses (Quarter) stood at $10.5 million in 2021, then surged by 33.71% to $14.1 million in 2022, then grew by 10.57% to $15.6 million in 2023, then dropped by 22.45% to $12.1 million in 2024, then tumbled by 36.22% to $7.7 million in 2025.
  • Its Accumulated Expenses was $7.7 million in Q3 2025, compared to $8.0 million in Q2 2025 and $9.2 million in Q1 2025.